Lulizumab pegol explained

Lulizumab pegol (INN;[1] development code BMS-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases.[2]

This drug was developed by Bristol-Myers Squibb.

References

  1. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111 . WHO Drug Information . 28 . 2 . 2014 .
  2. http://www.ama-assn.org/resources/doc/usan/x-pub/lulizumab-pegol.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Lulizumab Pegol

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Lulizumab pegol".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.